ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.9518
0.05%
Brent Oil
84.125
0.70%
Bitcoin
57,806.49
-0.74%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Redhill Biopharma Ltd (RDHL)

  7. Redhill Biopharma Ltd (RDHL) Noticias

RDHL

Redhill Biopharma (RDHL)

Redhill Biopharma Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RDHL
FechaHoraFuenteTítuloSímboloCompañía
24/04/202406:00PR Newswire (US)RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 StudyNASDAQ:RDHLRedhill Biopharma Ltd
08/04/202408:23PR Newswire (US)RedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsNASDAQ:RDHLRedhill Biopharma Ltd
02/04/202406:00PR Newswire (US)RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market PriceNASDAQ:RDHLRedhill Biopharma Ltd
11/03/202406:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:RDHLRedhill Biopharma Ltd
11/03/202406:00PR Newswire (US)RedHill Announces New USPTO Patent Covering Talicia® Through 2034NASDAQ:RDHLRedhill Biopharma Ltd
05/03/202406:00PR Newswire (US)RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures ProgramsNASDAQ:RDHLRedhill Biopharma Ltd
20/02/202406:00PR Newswire (US)RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationNASDAQ:RDHLRedhill Biopharma Ltd
16/02/202407:54Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RDHLRedhill Biopharma Ltd
15/02/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RDHLRedhill Biopharma Ltd
05/02/202407:00Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RDHLRedhill Biopharma Ltd
02/02/202415:10Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RDHLRedhill Biopharma Ltd
26/01/202411:46PR Newswire (US)RedHill Biopharma Announces Closing of $8 Million Registered Direct OfferingNASDAQ:RDHLRedhill Biopharma Ltd
26/01/202408:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RDHLRedhill Biopharma Ltd
25/01/202408:05PR Newswire (US)RedHill Biopharma Announces $8 Million Registered Direct OfferingNASDAQ:RDHLRedhill Biopharma Ltd
25/01/202405:00PR Newswire (US)RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042NASDAQ:RDHLRedhill Biopharma Ltd
20/12/202307:45PR Newswire (US)RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against EbolaNASDAQ:RDHLRedhill Biopharma Ltd
12/12/202306:00PR Newswire (US)RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:RDHLRedhill Biopharma Ltd
04/12/202306:00PR Newswire (US)RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 StudyNASDAQ:RDHLRedhill Biopharma Ltd
27/11/202306:00PR Newswire (US)RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034NASDAQ:RDHLRedhill Biopharma Ltd
14/11/202307:00PR Newswire (US)RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital MarketNASDAQ:RDHLRedhill Biopharma Ltd
23/10/202315:06Edgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:RDHLRedhill Biopharma Ltd
13/10/202307:13Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:RDHLRedhill Biopharma Ltd
03/10/202306:00PR Newswire (US)RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo StudyNASDAQ:RDHLRedhill Biopharma Ltd
22/09/202315:15PR Newswire (US)RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:RDHLRedhill Biopharma Ltd
18/09/202306:00PR Newswire (US)RedHill Announces FDA sNDA Approval for Talicia®NASDAQ:RDHLRedhill Biopharma Ltd
05/09/202306:00PR Newswire (US)RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)NASDAQ:RDHLRedhill Biopharma Ltd
17/08/202306:00PR Newswire (US)RedHill Biopharma Provides H1/23 Financial Results and Operational HighlightsNASDAQ:RDHLRedhill Biopharma Ltd
01/08/202306:00PR Newswire (US)RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.NASDAQ:RDHLRedhill Biopharma Ltd
31/07/202306:00PR Newswire (US)RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDANASDAQ:RDHLRedhill Biopharma Ltd
25/07/202314:58PR Newswire (US)RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant ExerciseNASDAQ:RDHLRedhill Biopharma Ltd
 Showing the most relevant articles for your search:NASDAQ:RDHL

Su Consulta Reciente

USOTC
RHHBY
Roche (QX)
NASDAQ
MSFT
Microsoft
NYSE
XOM
Exxon Mobil
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
XLV
Health Care Select Sector
NASDAQ
TSLA
Tesla
NYSE
MCD
McDonalds
NASDAQ
GOOGL
Alphabet
NASDAQ
AAPL
Apple
USOTC
BASFY
BASF (QX)
AMEX
SPY
SPDR S&P 500
FX
EURUSD
Euro vs US Dollar
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
COIN
SOLUSD
Solana
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados